Peptide-drug Conjugate Information
General Information of This Peptide-drug Conjugate (PDC)
| PDC ID |
PDC_00154
|
|||||
|---|---|---|---|---|---|---|
| PDC Name |
GE11-DOX conjugate
|
|||||
| PDC Status |
Investigative
|
|||||
| Indication |
In total 2 Indication(s)
Hepatocellular carcinoma
Breast cancer
|
|||||
| Structure |
|
|||||
| Peptide Name |
GE11 peptide
|
Peptide Info | ||||
| Receptor Name |
Epidermal growth factor receptor (EGFR)
|
Receptor Info | ||||
| Drug Name |
Doxorubicin
|
Drug Info | ||||
| Therapeutic Target |
DNA topoisomerase 2-alpha (TOP2A)
|
Target Info | ||||
| Linker Name |
Disulfide bond
|
Linker Info | ||||
| Formula |
C126H161N27O42S2
|
|||||
| #Ro5 Violations (Lipinski): 5 | Molecular Weight | 2789.955 | ||||
| Lipid-water partition coefficient (xlogp) | -10.2927 | |||||
| Hydrogen Bond Donor Count (hbonddonor) | 37 | |||||
| Hydrogen Bond Acceptor Count (hbondacc) | 45 | |||||
| Rotatable Bond Count (rotbonds) | 80 | |||||
Full List of Activity Data of This Peptide-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Hepatocellular carcinoma | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.87 µM
|
|||
| In Vitro Model | Hepatocellular carcinoma | SMMC-7721 cell | CVCL_0534 | ||
| Experiment 2 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
3.66 µM
|
|||
| In Vitro Model | Invasive breast carcinoma of no special type | EGFR-overexpressing MCF-7 cell | CVCL_0031 | ||
| Experiment 3 Reporting the Activity Data of This PDC | [1] | ||||
| Indication | Breast cancer | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
32.2µM
|
|||
| In Vitro Model | Invasive breast carcinoma | MCF-7 cell | CVCL_0031 | ||
References